Additionally, key markers (CD90, CD248, and FAP) identified through this analysis were validated using immunohistochemistry, further supported by historical data, reinforcing their potential as therapeutic targets or biomarkers for RA. This evidence concerns the gene FAP and rheumatoid arthritis.